• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

亚太地区医疗器械领域趋同与协调的监管依赖

Regulatory reliance for convergence and harmonisation in the medical device space in Asia-Pacific.

机构信息

Department of Global Health, Peking University School of Public Health, Beijing, China.

Lead for China, Asia Pacific Medical Technology Association, Beijing, China

出版信息

BMJ Glob Health. 2022 Aug;7(8). doi: 10.1136/bmjgh-2022-009798.

DOI:10.1136/bmjgh-2022-009798
PMID:35985696
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9395591/
Abstract

While some sort of regulatory convergence and harmonisation are often needed for achieving regulatory reliance, in reality, regulatory reliance as a strategy towards convergence and harmonisation has never been more significant in Asia-Pacific (APAC). A sustained, rapid and large-scale provision of medical devices, including articles and apparatus used in diagnosis, care, treatment or prevention of disease and softwares, etc, across national boundaries, is the key to winning the fight against future pandemics and improving people's well-being in such a populous and geographically diverse region. The COVID-19 pandemic highlighted the value of regulatory reliance to enable easier access to medical devices that have gone through regulatory approvals in countries with mature regulatory systems based on the Quality Management System and product assessment guidelines of the International Medical Device Regulators Forum. This analysis focuses on why regulatory reliance is needed, how much has been achieved, its impact on the development of the medical device industry and challenges to be addressed in the region. By drawing on the experience from the Singapore Health Sciences Authority-Thai Food and Drug Administration regulatory reliance pilot and Vietnam's inclusion of Korea Ministry of Food and Drug Safety and China National Medical Products Administration as reference markets for fast review/approval, it aims to explore next viable steps and future trend of the APAC regional regulatory harmonisation mechanism through regulatory reliance in the post-COVID-19 era.

摘要

虽然为了实现监管互认,通常需要进行某种程度的监管趋同和协调,但在现实中,监管互认作为一种趋同和协调的策略,在亚太地区(APAC)从未像现在这样重要。在这样一个人口众多、地域多样的地区,要想赢得未来对抗大流行病的斗争并改善人民福祉,关键是要在国家间持续、快速、大规模地提供医疗器械,包括用于诊断、护理、治疗或预防疾病的器械和软件等。COVID-19 大流行凸显了监管互认的价值,使人们更容易获得已在具有成熟监管体系的国家获得监管批准的医疗器械,这些国家的监管体系基于国际医疗器械监管者论坛的质量管理体系和产品评估准则。本分析重点关注为什么需要监管互认、已经取得了多少成就、它对医疗器械行业发展的影响以及该地区需要解决的挑战。通过借鉴新加坡卫生科学局-泰国食品药品监督管理局监管互认试点项目的经验,以及越南将韩国食品药品安全部和中国国家药品监督管理局作为快速审查/批准的参考市场纳入其中的经验,旨在探索在后 COVID-19 时代通过监管互认实现亚太地区监管协调机制的可行步骤和未来趋势。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ec9/9395591/f17da9989879/bmjgh-2022-009798f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ec9/9395591/5bd4b6f42a04/bmjgh-2022-009798f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ec9/9395591/f17da9989879/bmjgh-2022-009798f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ec9/9395591/5bd4b6f42a04/bmjgh-2022-009798f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ec9/9395591/f17da9989879/bmjgh-2022-009798f02.jpg

相似文献

1
Regulatory reliance for convergence and harmonisation in the medical device space in Asia-Pacific.亚太地区医疗器械领域趋同与协调的监管依赖
BMJ Glob Health. 2022 Aug;7(8). doi: 10.1136/bmjgh-2022-009798.
2
Measuring Progress of Regulatory Convergence and Cooperation Among Asia-Pacific Economic Cooperation (APEC) Member Economies in the Context of the COVID-19 Pandemic.衡量亚太经合组织(APEC)成员经济体在 COVID-19 大流行背景下的监管趋同和合作进展。
Ther Innov Regul Sci. 2021 Jul;55(4):786-798. doi: 10.1007/s43441-021-00285-w. Epub 2021 Apr 11.
3
Gap analysis in manufacturing, innovation and marketing of medical devices in the Asia-Pacific region.亚太地区医疗器械制造、创新和营销的差距分析。
Expert Rev Pharmacoecon Outcomes Res. 2022 Oct;22(7):1043-1050. doi: 10.1080/14737167.2022.2086122. Epub 2022 Jun 8.
4
Asia Partnership Conference of Pharmaceutical Associations (APAC) Report on Regulatory Agility Implemented During the COVID-19 Pandemic: Inspiring Partnerships and Recommendations for the Way Forward.亚洲制药协会伙伴关系会议(APAC)在 COVID-19 大流行期间实施监管敏捷性的报告:激发伙伴关系的建议和前进道路。
Ther Innov Regul Sci. 2023 Jan;57(1):12-25. doi: 10.1007/s43441-022-00435-8. Epub 2022 Sep 29.
5
Report for the Eighth Asian National Control Laboratory Network meeting in 2023: Self-sufficiency strategy of plasma-derived medicinal products and regulatory harmonisation.2023 年第八届亚洲国家控制实验室网络会议报告:血液制品自给自足策略和监管协调。
Biologicals. 2024 Feb;85:101754. doi: 10.1016/j.biologicals.2024.101754. Epub 2024 Mar 1.
6
Medicinal Product Development and Regulatory Agilities Implemented During the Early Phases of the COVID-19 Pandemic: Experiences and Implications for the Future-An Industry View.COVID-19 大流行早期实施的药品开发和监管机构:经验与未来展望——行业观点。
Ther Innov Regul Sci. 2023 Sep;57(5):940-951. doi: 10.1007/s43441-023-00536-y. Epub 2023 Jun 2.
7
Worldwide Regulatory Reliance: Launching a Pilot on a Chemistry, Manufacturing, and Control Post Approval Change for a Vaccine.全球监管依赖:启动疫苗上市后变更的化学、制造和控制部分的试点。
PDA J Pharm Sci Technol. 2024 Aug 23;78(4):388-398. doi: 10.5731/pdajpst.2023.012850.
8
"What's Keeping Me Up at Night?" Reflections on the COVID-19 Pandemic in Asia.“让我夜不能寐的是什么?”对亚洲 COVID-19 大流行的反思。
Int J Technol Assess Health Care. 2022 Jun 15;38(1):e51. doi: 10.1017/S0266462322000381.
9
Reliance is key to effective access and oversight of medical products in case of public health emergencies.在发生公共卫生紧急情况时,有效获取和监督医疗产品的关键是依赖。
Expert Rev Clin Pharmacol. 2022 Jul;15(7):805-810. doi: 10.1080/17512433.2022.2088503. Epub 2022 Aug 9.
10
A Global Industry Survey on Post-Approval Change Management and Use of Reliance.药品上市后变更管理和依赖使用的全球行业调查
Ther Innov Regul Sci. 2024 Nov;58(6):1094-1107. doi: 10.1007/s43441-024-00681-y. Epub 2024 Aug 23.

引用本文的文献

1
Advancing Regulatory Oversight of Medical Device Trials to Align with Clinical Drug Standards in the European Union.推进欧盟医疗器械试验的监管监督,使其与临床药物标准保持一致。
Pharmaceuticals (Basel). 2025 Jun 12;18(6):876. doi: 10.3390/ph18060876.
2
Regulatory landscape of accelerated approval pathways for medical devices in the United States and the European Union.美国和欧盟医疗器械加速批准途径的监管格局。
Front Med Technol. 2025 May 15;7:1586070. doi: 10.3389/fmedt.2025.1586070. eCollection 2025.
3
Improving the efficiency of the regulatory approvals of HIV in vitro diagnostics in low- and middle-income countries: Perspective of the IAS Industry Liaison Forum diagnostic partners.

本文引用的文献

1
Strengthening regulatory systems for medicines in a changed world: where do we go from here?在不断变化的世界中加强药品监管体系:我们从何去何从?
BMJ Glob Health. 2021 Jan;6(1). doi: 10.1136/bmjgh-2020-004680.
2
Global regulatory agility during covid-19 and other health emergencies.新冠疫情及其他卫生紧急情况期间的全球监管灵活性。
BMJ. 2020 Apr 27;369:m1575. doi: 10.1136/bmj.m1575.
3
The need for global regulatory harmonization: A public health imperative.全球监管协调的必要性:一项公共卫生要务。
提高低收入和中等收入国家艾滋病毒体外诊断试剂监管审批效率:国际艾滋病协会行业联络论坛诊断合作伙伴的观点
PLOS Glob Public Health. 2025 Apr 10;5(4):e0004169. doi: 10.1371/journal.pgph.0004169. eCollection 2025.
4
Evidence-based recommendations for comprehensive regulatory guidelines in medical devices: the imperative for global harmonization.医疗器械综合监管指南的循证建议:全球协调的必要性。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Feb 5. doi: 10.1007/s00210-025-03843-3.
5
WHO-listed authorities (WLA) framework: transparent evidence-based approach for promoting regulatory reliance towards increased access to quality-assured medical products.世界卫生组织认可当局(WLA)框架:一种基于证据的透明方法,用于促进监管互认,以增加获得质量保证医疗产品的机会。
Front Med (Lausanne). 2024 Sep 23;11:1467229. doi: 10.3389/fmed.2024.1467229. eCollection 2024.
6
Factors associated with the utilization of diagnostic tools among countries with different income levels during the COVID-19 pandemic.在 COVID-19 大流行期间,不同收入水平国家对诊断工具的使用情况与哪些因素有关。
Glob Health Res Policy. 2023 Oct 27;8(1):45. doi: 10.1186/s41256-023-00330-1.
7
Future directions in regulatory affairs.监管事务的未来发展方向。
Front Med (Lausanne). 2023 Jan 9;9:1082384. doi: 10.3389/fmed.2022.1082384. eCollection 2022.
Sci Transl Med. 2016 May 11;8(338):338ed6. doi: 10.1126/scitranslmed.aaf1396.